OKYO Pharma (NASDAQ:OKYO) Earns “Buy” Rating from HC Wainwright

OKYO Pharma (NASDAQ:OKYO)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $7.00 price objective on the stock.

OKYO Pharma Trading Up 3.0 %

Shares of NASDAQ OKYO traded up $0.03 during mid-day trading on Wednesday, reaching $1.05. The company had a trading volume of 24,203 shares, compared to its average volume of 126,342. OKYO Pharma has a 52 week low of $0.81 and a 52 week high of $2.12. The business’s 50-day moving average is $1.04 and its 200-day moving average is $1.26.

OKYO Pharma Company Profile

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.